Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study

Journal:

Nature Communications

Published:

2026-03-25

DOI:

10.1038/s41467-026-69708-2

Affiliations:

22

Authors:

18

Go to article

Institutions	Authors	Share
The University of Texas MD Anderson Cancer Center, United States of America (USA)	2.000000	0.11
Epizyme, Inc., United States of America (USA)	2.000000	0.11
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.06
Weill Cornell Medicine, United States of America (USA)	1.000000	0.06
IRCCS National Cancer Institute (INT) Milan, Italy	1.000000	0.06
Northwestern University (NU), United States of America (USA)	1.000000	0.06
University of Michigan Rogel Cancer Center, United States of America (USA)	1.000000	0.06
University of California, San Francisco (UCSF), United States of America (USA)	1.000000	0.06
University College Hospital (UCH), United Kingdom (UK)	1.000000	0.06
Institut de Cancérologie Strasbourg Europe (ICANS), France	1.000000	0.06
Harvard Medical School (HMS), United States of America (USA)	0.833333	0.05
University Hospitals Leuven (UZ Leuven), Belgium	0.500000	0.03
Catholic University of Leuven (KU Leuven), Belgium	0.500000	0.03
The Royal Marsden NHS Foundation Trust, United Kingdom (UK)	0.500000	0.03
The Institute of Cancer Research (ICR), United Kingdom (UK)	0.500000	0.03
Massachusetts General Hospital Cancer Center, United States of America (USA)	0.500000	0.03
The Hospital for Sick Children (SickKids), U of T, Canada	0.500000	0.03
Princess Margaret Cancer Centre, U of T, Canada	0.500000	0.03
National Taiwan University Hospital (NTUH), Taiwan	0.500000	0.03
National Taiwan University (NTU), Taiwan	0.500000	0.03
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	0.333333	0.02
Ludwig Center at Harvard Medical School, United States of America (USA)	0.333333	0.02

Interested in Oncology and Carcinogenesis?